|1.||Matsumoto, K: 9 articles (07/2001 - 01/2000)|
|2.||Morishita, Y: 9 articles (05/2001 - 01/2000)|
|3.||Takeyoshi, I: 9 articles (05/2001 - 01/2000)|
|4.||Tanaka, Noriyuki: 7 articles (01/2012 - 06/2004)|
|5.||Ohwada, S: 7 articles (03/2001 - 01/2000)|
|6.||Sato, Hiroaki: 6 articles (01/2012 - 06/2004)|
|7.||Tanaka, Toshiko: 6 articles (01/2012 - 06/2004)|
|8.||Kawashima, Y: 6 articles (05/2001 - 09/2000)|
|9.||Takeyoshi, Izumi: 5 articles (03/2009 - 08/2002)|
|10.||Kasai, Kentaro: 5 articles (05/2008 - 06/2004)|
01/01/2000 - "In this report we investigated the dose of FR167653 effective in pulmonary ischemia-reperfusion injury in a canine model. "
02/01/1999 - "FR167653 ameliorates pulmonary ischemia-reperfusion injury."
11/01/1998 - "FR167653 ameliorates pulmonary ischemia-reperfusion injury in dogs."
04/01/2000 - "We designed this experimental study to evaluate the effect of FR167653 on ischemia-reperfusion injury of the rat lung. "
11/01/1998 - "Effects of FR167653 on pulmonary ischemia-reperfusion injury in rats: a preliminary study."
01/01/2000 - "In a previous study, we reported the efficacy of FR167653 in canine ischemia-reperfusion models. "
11/01/2004 - "Studies were performed with isolated, Langendorff-perfused Lewis rat hearts (n=80) which were either treated with FR167653 or untreated, as the control group, and subjected to ischemia-reperfusion. "
11/01/2004 - "In this study, a newly synthesized cytokine inhibitor FR167653 was investigated using a rat heart ischemia-reperfusion model to prove its myocardial protective effect and its role in the inhibition of cytokine production in ischemic myocardium. "
08/01/1998 - "In this study, we evaluated the effect of FR167653 in an extended liver resection with ischemia in a dog model. "
05/01/2003 - "Attenuation of microcirculatory disturbance after liver ischemia by newly synthesized inflammatory cytokine suppressor, FR167653."
08/01/2004 - "Liver histopathological examination showed FR167653 (100, 150 mg/kg) significantly reduced inflammatory cells infiltration and liver cells necrosis. "
03/01/2002 - "FR167653 significantly decreased cell infiltration into outer medulla, and the extent of acute tubular necrosis 24 and 48 h after reperfusion. "
09/01/2004 - "Adding to this, our study demonstrated that FR167653 prevented renal failure, such as the infiltration of inflammatory cells and tubular cell necrosis after hemorrhage, and the intestinal barrier damage was also dramatically improved by FR167653 treatment. "
03/01/2002 - "FR167653 markedly decreased the transcription of interleukin-1beta, tumour necrosis factor-alpha, monocyte chemoattractant protein-1 and regulated upon activation, normal T cell expression and secreted in diseased kidneys. "
12/01/1999 - "Both dexamethasone and FR167653 (an inhibitor of interleukin-1 beta/tumour necrosis factor-alpha production) also reduced the severity of intestinal lesions as well as the increase in iNOS activity following administration of indomethacin. "
12/01/2002 - "The production of IL-8 and GRO-alpha was investigated and the effects of FR167653 were examined in a rabbit model of endotoxin shock. "
05/30/1997 - "The present study evaluated the efficacy of FR167653 (1-[7-(4-fluorophenyl)-1,2,3,4-tetrahydro-8-pyridylpyrazolo[5,1-c] [1,2,4]triazin-2-yl]-2-phenylethanedione sulfate monohydrate), a dual inhibitor of interleukin-1 and TNF-alpha production, to protect rabbits from the shock and lethality induced by lipopolysaccharide. "
05/30/1997 - "FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock."
12/01/2002 - "Altogether, these data suggest the possible involvement of IL-8 and GRO-alpha in endotoxin shock, and FR167653 may foster a beneficial outcome in part by modulating the chemokines level by inhibiting TNF-alpha and IL-1beta."
12/01/2001 - "FR167653 might locally affect arthritic joints to prevent inflammation. "
08/01/2000 - "In addition, there was marked reduction in renal injury even when FR167653 treatment was initiated after glomerular inflammation was established, suggesting that the therapeutic application of FR167653 may be clinically useful for human renal diseases."
01/01/2012 - "FR167653 inhibited the inflammation-related hepatic injury following hemorrhagic shock. "
01/01/2012 - "Compared with either agent alone, a combination of fasudil and FR167653 was more effective for the improvement of myocardial damage, inflammation and oxidative stress. "
06/01/2004 - "We measured the expression levels of genes and proteins related to inflammation in human vascular smooth muscle cells (hVSMCs) treated with hemolysate and FR167653 (FR) (1 micromol/L), a selective p38MAPK inhibitor, for 48 hours by TaqMan real-time reverse transcription-polymerase chain reaction (RT-PCR) and ELISA. "
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|2.||Interleukin-1 (Interleukin 1)
|3.||p38 Mitogen-Activated Protein Kinases
|5.||Interleukin-1beta (Interleukin 1 beta)
|6.||Protein Kinases (Protein Kinase)
|7.||Interleukin-8 (Interleukin 8)
|4.||Heart Transplantation (Grafting, Heart)